UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 37

Sortiert nach

Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate [Corrigendum]

International journal of chronic obstructive pulmonary disease, 2021-05, Vol.16, p.1347-1348

2021

Volltextzugriff (PDF)

The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies [Corrigendum]

International journal of chronic obstructive pulmonary disease, 2020-05, Vol.15, p.1177-1178

2020

Volltextzugriff (PDF)

Impact of Comorbidity Prevalence and Cardiovascular Disease Status on the Efficacy and Safety of Nebulized Glycopyrrolate in Patients with COPD

International journal of chronic obstructive pulmonary disease, 2021-01, Vol.16, p.1061-1073

2021

Volltextzugriff (PDF)

Effect of SGRQ-Defined Chronic Bronchitis at Baseline on Treatment Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate

International journal of chronic obstructive pulmonary disease, 2021-01, Vol.16, p.945-955

2021

Volltextzugriff (PDF)

Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate

International journal of chronic obstructive pulmonary disease, 2020-01, Vol.15, p.995-1004

2020

Volltextzugriff (PDF)

Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies

International journal of chronic obstructive pulmonary disease, 2021-01, Vol.16, p.865-875

2021

Volltextzugriff (PDF)

The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies

International journal of chronic obstructive pulmonary disease, 2020-01, Vol.15, p.745-754

2020

Volltextzugriff (PDF)

Efficacy and safety of glycopyrrolate in patients with COPD by reversibility: pooled analysis of GEM1 and GEM2 12-week studies

International journal of chronic obstructive pulmonary disease, 2019-01, Vol.14, p.461-470

2019

Volltextzugriff (PDF)

P813: EFFICACY, TREATMENT ADMINISTRATION SATISFACTION AND SAFETY OF SUBCUTANEOUS RAVULIZUMAB THROUGH 1 YEAR IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO RECEIVED PRIOR INTRAVENOUS ECULIZUMAB

HemaSphere, 2022-06, Vol.6 (Suppl), p.707-708

2022

Volltextzugriff (PDF)

CORRIGENDUM

International journal of chronic obstructive pulmonary disease, 2021-05, Vol.16, p.1347

2021

Volltextzugriff (PDF)

A37 THE SPECTRUM OF COPD: EPIDEMIOLOGY TO OUTCOMES: Patient Device Satisfaction With Eflow Closed System Nebulizer: Results From The Golden-5 Study In Patients With Moderate-To Very-Severe Chronic Obstructive Pulmonary Disease (COPD)

American journal of respiratory and critical care medicine, 2017-01, Vol.195

2017

Volltextzugriff (PDF)

A37 THE SPECTRUM OF COPD: EPIDEMIOLOGY TO OUTCOMES: Health-Related Quality Of Life (hrqol) In Moderate-To-Very Severe Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Sun-101 (glycopyrrolate/eflow®): Findings From The Phase 3 Golden Studies

American journal of respiratory and critical care medicine, 2017-01, Vol.195

2017

Volltextzugriff (PDF)

C49 COPD: TREATMENT: Improvement In Respiratory Symptoms In Moderate-To-Very Severe Chronic Obstructive Pulmonary Disease Patients Treated With Sun-101 (glycopyrrolate/eflow®) - Patient-Reported Outcomes From The Phase 3 Golden Studies

American journal of respiratory and critical care medicine, 2017-01, Vol.195

2017

Volltextzugriff (PDF)

Fraction of Design Space Plots for Examining Model Robustness

Journal of quality technology, 2005-07, Vol.37 (3), p.223-235

2005

Volltextzugriff (PDF)

Prediction Variance Properties of Second-Order Designs for Cuboidal Regions

Journal of quality technology, 2005-10, Vol.37 (4), p.253-266

2005

Volltextzugriff (PDF)

P813: EFFICACY, TREATMENT ADMINISTRATION SATISFACTION AND SAFETY OF SUBCUTANEOUS RAVULIZUMAB THROUGH 1 YEAR IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO RECEIVED PRIOR INTRAVENOUS ECULIZUMAB

HemaSphere, 2022-06, Vol.6, p.707-708

2022

Volltextzugriff (PDF)

Effect of smoking status on lung function, patient-reported outcomes, and safety among COPD patients treated with glycopyrrolate inhalation powder: pooled analysis of GEM1 and GEM2 studies

Respiratory research, 2019-07, Vol.20 (1), p.135-10, Article 135

2019

Volltextzugriff (PDF)

Evaluation of systemic absorption and bronchodilator effect of glycopyrronium bromide delivered by nebulizer or a dry powder inhaler in subjects with chronic obstructive pulmonary disease

Respiratory research, 2019-06, Vol.20 (1), p.132-12, Article 132

2019

Volltextzugriff (PDF)

Response letter to Dr. Blackwelder and Dr. Reed’s letter regarding “On the use of nonparametric tests for comparing immunological reverse cumulative distribution curves (RCDCs)”

Vaccine, 2020-05, Vol.38 (25), p.4058-4058

2020

Volltextzugriff (PDF)

On the use of nonparametric tests for comparing immunological Reverse Cumulative distribution curves (RCDCs)

Vaccine, 2019-10, Vol.37 (44), p.6737-6742

2019

Volltextzugriff (PDF)

EFFICACY OF NEBULIZED ARFORMOTEROL FOR THE TREATMENT OF PATIENTS WITH COPD: A ROLE FOR LONG-ACTING BRONCHODILATORS IN TREATING LONG-TERM CARE PATIENTS WITH COPD

Chest, 2019-10, Vol.156 (4), p.A461-A462

2019

Volltextzugriff (PDF)

AN ASSESSMENT OF TIME TO ONSET OF BRONCHODILATION FOLLOWING TREATMENT WITH NEBULIZED ARFORMOTEROL IN PATIENTS WITH COPD

Chest, 2019-10, Vol.156 (4), p.A1622-A1623

2019

Volltextzugriff (PDF)

Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up

Advances in therapy, 2023-01, Vol.40 (1), p.211-232

2023

Volltextzugriff (PDF)

Effect of smoking status on lung function, patient-reported outcomes, and safety among patients with COPD treated with indacaterol/glycopyrrolate: Pooled analysis of the FLIGHT1 and FLIGHT2 studies

Respiratory medicine, 2019-08, Vol.155, p.113-120

2019

Volltextzugriff (PDF)

Immunogenicity and safety of Fluzone® intradermal and high-dose influenza vaccines in older adults ≥65 years of age: A randomized, controlled, phase II trial

Vaccine, 2014-05, Vol.32 (21), p.2507-2517

2014

Volltextzugriff (PDF)

1 – 25 von 37

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(36)
Dissertationen
(1)

Sprache

Englisch
(37)

Erscheinungsjahr

n.n

Thema

Science & Technology
(24)
Life Sciences & Biomedicine
(21)
Copd
(14)
Humans
(14)
Respiratory System
(14)
Glycopyrrolate
(13)
Chronic Obstructive Pulmonary Disease
(12)
Patients
(10)
Female
(9)
Lama
(9)
Middle Aged
(9)
Adult
(8)
Male
(8)
Treatment Outcome
(8)
Aged
(7)
Glycine
(7)
Medicine, Research & Experimental
(7)
Original Research
(7)
Pulmonary Disease, Chronic Obstructive - Drug Therapy
(7)
Research & Experimental Medicine
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate [Corrigendum]

The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies [Corrigendum]

Impact of Comorbidity Prevalence and Cardiovascular Disease Status on the Efficacy and Safety of Nebulized Glycopyrrolate in Patients with COPD

Effect of SGRQ-Defined Chronic Bronchitis at Baseline on Treatment Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate

Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate

Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies

The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies

Efficacy and safety of glycopyrrolate in patients with COPD by reversibility: pooled analysis of GEM1 and GEM2 12-week studies

P813: EFFICACY, TREATMENT ADMINISTRATION SATISFACTION AND SAFETY OF SUBCUTANEOUS RAVULIZUMAB THROUGH 1 YEAR IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO RECEIVED PRIOR INTRAVENOUS ECULIZUMAB

CORRIGENDUM

A37 THE SPECTRUM OF COPD: EPIDEMIOLOGY TO OUTCOMES: Patient Device Satisfaction With Eflow Closed System Nebulizer: Results From The Golden-5 Study In Patients With Moderate-To Very-Severe Chronic Obstructive Pulmonary Disease (COPD)

A37 THE SPECTRUM OF COPD: EPIDEMIOLOGY TO OUTCOMES: Health-Related Quality Of Life (hrqol) In Moderate-To-Very Severe Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Sun-101 (glycopyrrolate/eflow®): Findings From The Phase 3 Golden Studies

C49 COPD: TREATMENT: Improvement In Respiratory Symptoms In Moderate-To-Very Severe Chronic Obstructive Pulmonary Disease Patients Treated With Sun-101 (glycopyrrolate/eflow®) - Patient-Reported Outcomes From The Phase 3 Golden Studies

Fraction of Design Space Plots for Examining Model Robustness

Prediction Variance Properties of Second-Order Designs for Cuboidal Regions

P813: EFFICACY, TREATMENT ADMINISTRATION SATISFACTION AND SAFETY OF SUBCUTANEOUS RAVULIZUMAB THROUGH 1 YEAR IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO RECEIVED PRIOR INTRAVENOUS ECULIZUMAB

Effect of smoking status on lung function, patient-reported outcomes, and safety among COPD patients treated with glycopyrrolate inhalation powder: pooled analysis of GEM1 and GEM2 studies

Evaluation of systemic absorption and bronchodilator effect of glycopyrronium bromide delivered by nebulizer or a dry powder inhaler in subjects with chronic obstructive pulmonary disease

Response letter to Dr. Blackwelder and Dr. Reed’s letter regarding “On the use of nonparametric tests for comparing immunological reverse cumulative distribution curves (RCDCs)”

On the use of nonparametric tests for comparing immunological Reverse Cumulative distribution curves (RCDCs)

EFFICACY OF NEBULIZED ARFORMOTEROL FOR THE TREATMENT OF PATIENTS WITH COPD: A ROLE FOR LONG-ACTING BRONCHODILATORS IN TREATING LONG-TERM CARE PATIENTS WITH COPD

AN ASSESSMENT OF TIME TO ONSET OF BRONCHODILATION FOLLOWING TREATMENT WITH NEBULIZED ARFORMOTEROL IN PATIENTS WITH COPD

Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up

Effect of smoking status on lung function, patient-reported outcomes, and safety among patients with COPD treated with indacaterol/glycopyrrolate: Pooled analysis of the FLIGHT1 and FLIGHT2 studies

Immunogenicity and safety of Fluzone® intradermal and high-dose influenza vaccines in older adults ≥65 years of age: A randomized, controlled, phase II trial

Suchergebnisse filtern